151330-02-8

Basic information

• Product Name: 7-Isoquinolinecarboxylic acid, 5,6,7,8-tetrahydro-8-oxo-, methyl ester
• Synonyms: Methyl 8-oxo-5,6,7,8-tetrahydroisoquinoline-7-carboxylate;methyl 6,7-dihydro-8(5H)-isoquinolinone-7-carboxylate
• CAS NO: 151330-02-8
• Molecular Formula: C11H11NO3
• Molecular Weight: 205.21000
• Mol File: 151330-02-8.mol

Chemical Properties

• CAS DataBase Reference: 7-Isoquinolinecarboxylic acid, 5,6,7,8-tetrahydro-8-oxo-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Isoquinolinecarboxylic acid, 5,6,7,8-tetrahydro-8-oxo-, methyl ester(151330-02-8)
• EPA Substance Registry System: 7-Isoquinolinecarboxylic acid, 5,6,7,8-tetrahydro-8-oxo-, methyl ester(151330-02-8)

Safety Data

• Hazardous Substances Data: 151330-02-8(Hazardous Substances Data)

Upstream product

• 55314-29-9 4-methylnicotinic acid ethyl ester 
• 292638-85-8 acrylic acid methyl ester 
• 33402-75-4 4-methylnicotinic acid methyl ester 
• 3222-50-2 4-methylnicotinic acid 

Downstream Products

• 21917-88-4 6, 7-dihydro-5H-isoquinolin-8-one 

Relevant articles and documents

CYCLOALKANOPYRIDINE DERIVATIVE

Provided are cycloalkanopyridine derivatives of formula [I]: [wherein the symbols are the same as those stated in the description]. The compounds act as a nociceptin receptor antagonist, and are useful as medicines for diseases associated with a nociceptin receptor, for example, as a reliever against tolerance to a narcotic analgesic; a reliever against dependence on or addiction to a narcotic analgesic; an analgesic enhancer; an antiobesitic or appetite suppressor; a treating or prophylactic agent for cognitive impairment and dementia/amnesia; an agent for treating developmental cognitive abnormality; a remedy for schizophrenia; an agent for treating neurodegenerative diseases; an anti-depressant or treating agent for affective disorder; a treating or prophylactic agent for diabetes insipidus; a treating or prophylactic agent for polyuria; or a remedy for hypotension.

Synthesis, optical resolution, absolute configuration, and preliminary pharmacology of (+)- and (-)-cis-2,3,3a,4,5,9b-hexahydro-1-methyl-1H-pyrrolo- [3,2-h]isoquinoline, a structural analog of nicotine

Title compound, 8, has been synthesized from isoquinolinone, 1 (an improved preparation for which is presented) and separated into its antipodes with D- and L-di-p-toluoyltartaric acids. These antipodes and the racemic precursor have been evaluated (and found active) in two in vivo systems for their effects. The most potent of the three, (+)-8, has an ED50 of 7.13 μmol/kg for inhibition of spontaneous activity and 7.45 μmol/kg for antinociception compared to 4.44 and 4.81 μmol/kg, respectively, for (S)-(- )-nicotine. Compounds (-)-8 and 7 are about one-fourth as potent. Isomer (+)- 8 has the 3aR,9bS configuration, the latter corresponding to (S)-(-)-nicotine as determined by X-ray crystallography. However, (+)-8 failed to compete for [3H]-nicotine binding, and its pharmacological effects were not blocked by mecamylamine. These bridged nicotine analogs either are binding to an as- yet-unidentified nicotinic receptor or they represent a novel class of non- nicotinic analgesics.